AGS 67E

Drug Profile

AGS 67E

Alternative Names: AGS67E

Latest Information Update: 27 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Agensys
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Apr 2016 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA, Canada (IV) (NCT02610062)
  • 01 Aug 2014 Phase-I clinical trials in Hairy cell leukaemia, Lymphoid leukaemia, Non-Hodgkin's lymphoma and Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (IV)
  • 24 Jun 2014 Agensys plans a phase I trial for Lymphoid malignancies (Second-line therapy or greater) in USA and Canada (NCT02175433)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top